Inclusion Criteria:  Noninfectious immunocompetent participants (i.e., healthy participants) as determined by medical history and clinical judgement.  or  Patients with primary immunodeficiencies or Patients with B-cell depleting therapy due to autoimmune disease or  Patients with benign and malignant hematological diseases receiving specific Treatments with known immunosuppressive effects including cytotoxic agents, systemic corticosteroids, monoclonal antibodies and targeted therapies.  or  Patients with active hematological diseases and secondary immunoglobulin deficiency (e.g. chronic lymphatic leukemia, MM) currently not receiving specific treatment.  or  Patients >3 months but <12 months after autologous HSCT (hematopoietic stem cell transplantation).  or  Patients >3 months but <12 months after allogeneic HSCT. or  Recipients of HSCT >12 months after allogeneic HSCT but under immunosuppressive therapy.  or  Patients with chronic GvHD (graft-versus-host disease) and persistent immunodeficiency.  Exclusion Criteria:  Healthy participants  Presence of diseases or therapies that are likely to interfere with the immune response to vaccination. Presence of a disease requiring change in therapy during 4 weeks before enrollment. Any contraindications to the vaccine planned to receive as listed in the product characteristics. Lack of willingness to undergo serial blood draws and attend follow-up appointments. Women who are pregnant or breastfeeding. Previous vaccination with any coronavirus vaccine. Persons who are not willing to sign the informed consents (biobank informed consent and study specific informed consent).  Immunodeficient participants  Patients with hematological diseases within three months from B-cell-depleting immunotherapy (rituximab, ofatumumab, obinutuzumab, blinatumomab, CAR-T cells (Chimeric Antigen Receptor). Patients with hematological malignancies in remission and >12 months after end of specific therapy. Patients within three months from HSCT. Any contraindications to the vaccine planned to receive as listed in the product characteristics. Lack of willingness to undergo serial blood draws and attend follow-up appointments. Women who are pregnant or breastfeeding. Previous vaccination with any coronavirus vaccine (exception: if serum prior to vaccination is available from the biobank). Patients who are not willing to sign the informed consents (biobank informed consent and study specific informed consent).